Savolitinib (savo) plus osimertinib (osi) vs savo plus placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi

被引：0
|
作者：
Yang, James Chih-Hsin
Chen, Yuh-Min
Batra, Ullas
Do, Kien
Sitthideatphaiboon, Piyada
Danchaivijitr, Pongwut
Lee, Kang-Yun
Chindaprasirt, Jarin
Yang, Cheng-Ta
Chang, Gee-Chen
Charoentum, Chaiyut
Ungtrakul, Teerapat
Moran, Juan Ignacio Hernandez
Hartmaier, Ryan
Haskins, Matthew
Xu, Wanning
Riess, Jonathan W.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT251
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT251
引用
收藏
页数：3
相关论文
共 49 条
  • [21] Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study
    Ramalingam, Suresh S.
    Saka, Hideo
    Ahn, Myung-Ju
    Yu, Helena
    Horn, Leora
    Hida, Toyoaki
    Cantarini, Mireille
    Verheijen, Remy
    Wessen, Jonathan
    Oxnard, Geoffrey
    Ohe, Yuichiro
    CANCER RESEARCH, 2019, 79 (13)
  • [22] A phase II study of Becotatug (JMT101) in combination with osimertinib (Osi) in patients (pts) with classical EGFR-mutated non-small cell lung cancer (NSCLC) (BOOSTER Study)
    Zhang, L.
    Fang, W. F.
    Zhao, S.
    Yu, Y.
    Yong, T. X.
    Dong, X.
    Zhuang, W.
    Hu, Y.
    Luo, F.
    Wang, Q.
    Chu, Q.
    Fu, Z.
    Yao, Y.
    Ma, X.
    Ding, C.
    Hao, J.
    Yang, X.
    Wan, X.
    Li, M.
    Yang, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1624 - S1625
  • [23] A real-world multi-center prospective observational study of atezolizumab (Atezo) plus bevacizumab (Bev) plus carboplatin (CBDCA) plus paclitaxel (PTX) (ABCP) in patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC after EGFR- TKIs failure
    Kuyama, S.
    Yoshioka, H.
    Kaneda, H.
    Kataoka, Y.
    Miura, S.
    Katakami, N.
    Yamanaka, Y.
    Tamiya, A.
    Yamada, T.
    Yokoyama, T.
    Hara, S.
    Tanaka, H.
    Fujisaka, Y.
    Nakamura, A.
    Azuma, K.
    Namba, M.
    Hata, A.
    Sawa, K.
    Ishikawa, H.
    Kurata, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S1572 - S1572
  • [24] Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial
    Passaro, A.
    Cho, B. C.
    Wang, Y.
    Melosky, B.
    Califano, R.
    Lee, S-H.
    Girard, N.
    Reckamp, K. L.
    Takahashi, T.
    Felip, E.
    Gentzler, R. D.
    Popat, S.
    William, W. Nassib, Jr.
    Sun, T.
    Shah, S.
    Diorio, B.
    Knoblauch, R. E.
    Bauml, J. M.
    Garcia-Campelo, M. R.
    Wang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1307 - S1307
  • [25] Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC
    Wehler, T.
    Wehler, B.
    Atmaca-Dirik, H.
    Schulz, C.
    Grohe, C.
    Topsch, J.
    Ehrlich, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S800 - S801
  • [26] A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients withEGFR-mutated,MET-amplified advanced non-small-cell lung cancer
    Yang, Jin-Ji
    Fang, Jian
    Shu, Yong-Qian
    Chang, Jian-Hua
    Chen, Gong-Yan
    He, Jian Xing
    Li, Wei
    Liu, Xiao-Qing
    Yang, Nong
    Zhou, Caicun
    Huang, Jian An
    Frigault, Melanie M.
    Hartmaier, Ryan
    Ahmed, Ghada F.
    Egile, Coumaran
    Morgan, Shethah
    Verheijen, Remy B.
    Mellemgaard, Anders
    Yang, Liu
    Wu, Yi-Long
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (02) : 477 - 487
  • [27] First-line (1L) osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC): FLAURA2 Asian cohort
    Yang, J. C-H.
    Kobayashi, K.
    Chewaskulyong, B.
    Tran, T. V.
    Biswas, B.
    Lee, K. H.
    Feng, P-H.
    Pham, X. D.
    Yao, Y.
    Kuyama, S.
    Bing, J. Y. Tan Chun
    Bhise, R.
    Ahn, M-J.
    Sriuranpong, V.
    Li, R. K.
    Monterroso, E. Armenteros
    Barrett, K.
    Albayaty, M.
    Cheng, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1635 - S1636
  • [28] Peripheral osimertinib (osi) plasma trough concentration (Cmin,SS) as surrogate parameter for development and progression of brain metastasis (BM) in patients (pts) with EGFR plus advanced non-small cell lung cancer (aNSCLC)
    Gulikers, J. L.
    Veerman, M. G. D.
    Jebbink, M.
    Kruithof, P.
    Steendam, C. M. J.
    Boosman, R.
    Mathijssen, R. H.
    Tjan-Heijnen, V.
    Driessen, A.
    Dursun, S.
    Smit, E. F.
    Dingemans, A-M. C.
    van Geel, R.
    Croes, S.
    Hendriks, L.
    ANNALS OF ONCOLOGY, 2023, 34
  • [29] CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report
    Kim, Dong-Wan
    Kim, Sang-We
    Camidge, D. Ross
    Shu, Catherine A.
    Marrone, Kristen A.
    Le, Xiuning
    Blakely, Collin M.
    Park, Keunchil
    Chang, Gee-Chen
    Patel, Sandip Pravin
    Kar, Gozde
    Cooper, Zachary A.
    Samadani, Ramin
    Pluta, Michael
    Kumar, Rakesh
    Ramalingam, Suresh
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (05) : 650 - 656
  • [30] Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes
    Planchard, D.
    Boyer, M.
    Lee, J-S.
    Dechaphunkul, A.
    Cheema, P.
    Takahashi, T.
    Todd, A.
    McKeown, A.
    Rukazenkov, Y.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2018, 29 : 169 - 169
12345